title: Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway.
abstract: Amyloid-β (Aβ) and tau are the pathogenic hallmarks in Alzheimer's disease (AD). Aβ oligomers are considered the actual toxic entities, and the toxicity relies on the presence of tau. Recently, Aβ oligomers have been shown to specifically interact with cellular prion protein (PrP(C)) where the role of PrP(C) in AD is still not fully understood. To investigate the downstream mechanism of PrP(C) and Aβ oligomer interaction and their possible relationships to tau, we examined tau expression in human neuroblastoma BE(2)-C cells transfected with murine PrP(C) and studied the effect under Aβ oligomer treatment. By Western blotting, we found that PrP(C) overexpression down-regulated tau protein and Aβ oligomer binding alleviated the tau reduction induced by wild type but not M128V PrP(C), the high AD risk polymorphic allele in human prion gene. PrP(C) lacking the Aβ oligomer binding site was incapable of rescuing the level of tau reduction. Quantitative RT-PCR showed the PrP(C) effect was attributed to tau reduction at the transcription level. Treatment with Fyn pathway inhibitors, Fyn kinase inhibitor PP2 and MEK inhibitor U0126, reversed the PrP(C)-induced tau reduction and Aβ oligomer treatment modulated Fyn kinase activity. The results suggested Fyn pathway regulated Aβ-PrP(C)-tau signaling. Overall, our results demonstrated that PrP(C) down-regulated tau via the Fyn pathway and the effect can be regulated by Aβ oligomers. Our study facilitated the understanding of molecular mechanisms among PrP(C), tau, and Aβ oligomers.
authors.affiliation: Graduate Institute of Life Sciences, National Defense Medical Center , Taipei, Taiwan.
authors.forename: Rong-Jie
authors.initials: RJ
authors.lastname: Chen
authors.forename: Wei-Wei
authors.initials: WW
authors.lastname: Chang
authors.forename: Yu-Chun
authors.initials: YC
authors.lastname: Lin
authors.forename: Pei-Lin
authors.initials: PL
authors.lastname: Cheng
authors.forename: Yun-Ru
authors.initials: YR
authors.lastname: Chen
mesh_terms: D000544:Alzheimer Disease / Q000235:genetics; D016229:Amyloid beta-Peptides / Q000494:pharmacology*; D000818:Animals; D002070:Butadienes / Q000494:pharmacology; D045744:Cell Line, Tumor; D015536:Down-Regulation; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects; D051379:Mice; D020125:Mutation, Missense; D009570:Nitriles / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology*; D017354:Point Mutation; D018621:PrPC Proteins / Q000235:genetics / Q000502:physiology*; D051076:Proto-Oncogene Proteins c-fyn / Q000037:antagonists & inhibitors / Q000502:physiology*; D011743:Pyrimidines / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D015398:Signal Transduction; D016875:tau Proteins / Q000096:biosynthesis* / Q000235:genetics
chemical_list: C412373:AG 1879; D016229:Amyloid beta-Peptides; D002070:Butadienes; D009570:Nitriles; D010446:Peptide Fragments; D018621:PrPC Proteins; D011743:Pyrimidines; D012333:RNA, Messenger; D011993:Recombinant Fusion Proteins; C113580:U 0126; C075222:amyloid beta-protein (1-42); D016875:tau Proteins; D051076:Proto-Oncogene Proteins c-fyn